Fennec Pharmaceuticals Inc.NASDAQ: FENC

Fennec Pharmaceuticals Announces Results of Annual Meeting

· Issued by Fennec Pharmaceuticals Inc. via GlobeNewswire

Summary by 6ix AI

Fennec Pharmaceuticals Inc. shareholders elected all five director nominees named in the April 28, 2026 management proxy circular at the company's Annual General and Special Meeting of Shareholders, held online.

Key details

  • Votes in favor of each director: Dr. Khalid Islam 13,858,131 (97.84 %), Mr. Chris A. Rallis 13,808,792 (97.49 %), Mr. Marco Brughera 13,807,501 (97.49 %), Dr. Jodi Cook 13,259,894 (93.62 %) and Mr. Jeff Hackman 13,495,309 (95.28 %).
  • Shareholders voted 99.64% in favor of appointing Haskell & White LLP as auditors and letting the directors set the auditor's pay.
  • Shareholders voted 85.50% in favor of the compensation paid to the company's named executive officers.
  • Shareholders voted 91.27% in favor of an amendment to the company's 2020 Equity Incentive Plan, or 88.01% after subtracting shares held by insiders eligible to take part in the plan.
  • For the plan amendment, the company relied on an exemption in Section 602.1 of the TSX (Toronto Stock Exchange) Company Manual, under which the TSX does not apply its standards to certain transactions by eligible companies also listed on a recognized exchange such as Nasdaq.

6ix AI wrote this summary from the release below and checked it against the release.

RESEARCH TRIANGLE PARK, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the "Company") (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy circular dated April 28, 2026 were elected as directors of the Company at the Annual General and Special Meeting of Shareholders held online on June 10, 2025.

Detailed results of the vote for the election of directors are set out below:

Name of NomineeVotes For% Votes ForVotes Withheld% Votes Withheld
Dr. Khalid Islam13,858,13197.84%304,7602.15%
Mr. Chris A. Rallis13,808,79297.49%354,0992.50%
Mr. Marco Brughera13,807,50197.49%355,3902.50%
Dr. Jodi Cook13,259,89493.62%902,9976.37%
Mr. Jeff Hackman13,495,30995.28%667,5824.71%

Shareholders voted 99.64% in favor of appointing Haskell & White LLP as auditors and authorizing the directors to fix the auditor remuneration, 85.50% in favor of the compensation paid to the Company's named executive officers, and 91.27% (88.01% after subtracting shares held by insiders eligible to participate in the Company's 2020 Equity Incentive Plan) in favor of certain amendment to the Company's 2020 Equity Incentive Plan.

The Company has relied on the exemption set forth in Section 602.1 of the TSX Company Manual, which provides that the TSX will not apply its standards to certain transactions involving eligible interlisted issuers on a recognized exchange, such as Nasdaq, in the approval of the amendments to its 2020 Equity Incentive Plan.

For further information, please contact:

Robert Andrade
Chief Financial Officer
Fennec Pharmaceuticals Inc.
Tel: 919-246-5299

Source: Fennec Pharmaceuticals Inc.

Fennec Pharmaceuticals Inc. on 6ix

Earlier from Fennec Pharmaceuticals

Later from Fennec Pharmaceuticals

All Fennec Pharmaceuticals news releases